Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-C, 10% Treatment in Subjects With Pure Occult Choroidal Neovascularization Due to Age Related Macular Degeneration

NCT00220805 is registered in ClinicalTrials.gov with Grifols Therapeutics LLC as lead sponsor.

NCT NCT00220805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00220805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-C, 10% Treatment in Subjects With Pure Occult Choroidal Neovascularization Due to Age Related Macular Degeneration
Lead sponsor
Grifols Therapeutics LLC
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2004
Completion date
May 31, 2005
Enrollment
96 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration